hemoglobin F

HbF's higher oxygen affinity results from decreased binding of 2,3-BPG (bisphosphoglycerate) to its gamma chains compared to HbA's beta chains, shifting the oxygen dissociation curve leftward. This allows the fetus to extract oxygen from the lower-oxygen-tension maternal blood across the placenta. HbF is the major hemoglobin during fetal life and gradually switches to HbA (α2β2) postnatally, with adult levels (HbF <1%) typically achieved by 6 months to 1 year of age via developmental globin gene switching (gamma to beta globin).

Clinically, HbF is significant in several contexts: 1. Hereditary persistence of fetal hemoglobin (HPFH) - a benign condition where HbF production continues into adulthood without pathology. 2. Beta-thalassemia and sickle cell disease - elevated HbF is protective, as it doesn't participate in sickling (lacks beta chains) and can ameliorate disease severity. Hydroxyurea, used therapeutically in sickle cell disease, works partly by increasing HbF production, reducing sickling events and vaso-occlusive crises. 3. Diagnostic utility - the Kleihauer-Betke test detects fetal red blood cells (containing HbF) in maternal circulation, used to quantify fetomaternal hemorrhage and determine appropriate Rh immunoglobulin (RhoGAM) dosing in Rh-negative mothers. 4. Neonatal screening - elevated HbF is normal in newborns but its persistence pattern helps diagnose various hemoglobinopathies.

Mechanistically, the alpha-like gene cluster on chromosome 16 and beta-like gene cluster on chromosome 11 undergo developmental regulation, with epsilon, gamma, delta, and beta genes expressed sequentially during development (hemoglobin switching).